- Fraisinib: a calixpyrrole derivative reducing A549 cell-derived NSCLC tumor in vivo acts as a ligand of the glycine-tRNA synthase, a new molecular target in oncology
Iméne Ben Toumia et al, 2024, Frontiers in Pharmacology CrossRef - Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines
Marika Saar et al, 2023, Pharmaceutics CrossRef - Interaction between NSCLC Cells, CD8+ T-Cells and Immune Checkpoint Inhibitors Potentiates Coagulation and Promotes Metabolic Remodeling—New Cues on CAT-VTE
Catarina Freitas-Dias et al, 2024, Cells CrossRef